Solid Biosciences Inc. Common Stock (SLDB)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach a company like Solid Biosciences with Graham's caution and Buffett's preference for understandable, cash-generating businesses. This is a 121-employee clinical-stage biotech targeting neuromuscular and cardiac diseases. Its lead candidate SGT-003 is in Phase 1/2 for Duchenne muscular dystrophy, with SGT-212 in Phase 1b for Friedreich's ataxia and earlier programs behind it. That pipeline is the entire investment case. There is no revenue in the filed figures — not in FY2023, FY2024, FY2025, or the fiscal quarters ended 2026-03-31 and 2026-06-30. Net losses have widened: FY2023 lost $96.0M, FY2024 lost $124.7M, and FY2025 lost $174.3M. In fiscal Q2 2026, the quarter ended 2026-06-30, the net loss was $54.8M, or $0.38 per diluted share; fiscal Q1 2026 lost $56.7M, or $0.52 per diluted share. Trailing free cash flow is -$187.8M, a -30.1% FCF yield on the $624.1M market cap. The balance sheet has low leverage — D/E 0.05 — and FairStock's Altman Z-Score is 5.54, but Piotroski is 2/9 and the FairStock Score is 26/100. At the 2026-10-13 close of $5.82, P/B is 1.63, but P/E is -3.08 and ROE is -65.50%, so earnings-based valuation offers no anchor. The moat is only theoretical: possible patents and orphan-drug exclusivity, no commercial product. Until data de-risk the pipeline and losses stop accelerating, this is a speculative binary bet, not a Graham-style bargain.

In plain English: Solid Biosciences is a small biotech company working on treatments for muscle and heart diseases. It has no product sales and has been losing more money each year. At $5.82 a share, the price looks speculative rather than clearly cheap because there are no profits or sales to support it.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer